Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1997 Jun;105(Suppl 4):739–747. doi: 10.1289/ehp.97105s4739

Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

B Burchell 1, M W Coughtrie 1
PMCID: PMC1470020  PMID: 9255555

Abstract

Glucuronidation and sulfation are phase 2 metabolic reactions catalyzed by large families of different isoenzymes in man. The textbook view that glucuronidation and sulfation lead to the production of harmless conjugates for simple excretion is not valid. Biologically active and toxic sulfates and glucuronides are produced and leed to adverse drug reactions, including immune hypersensitivity. Considerable variation in xenobiotic conjugation is observed as a result of altered expression of UDP-glucuronosyltransferases (UGTs) and sulfotransferases (STs). Recent cloning and expression of human cDNA encoding UGTs and STs has facilitated characterization of isoform substrate specificity, which has been further validated using specific antibodies and human tissue fractions. The availability of cloned/expressed human enzymes and specific antibodies has enabled the investigation of xenobiotic induction and metabolic disruption leeding to adverse responses. Genetic polymorphisms of glucuronidation and sulfation are known to exist although the characterization and assessment of the importance of these variations are hampered by appropriate ethical studies in men with suitable safe model compounds. Genetic analysis has allowed molecular identification of defects in well-known hyperbilirubinemias. However, full characterization of the specific functional roles of human UGTs and STs requires rigorous kinetic and molecular analyses of the role of each enzyme in vivo through the use of specific antibodies and inhibitors. This will leed to the better prediction of variation of xenobiotic glucuronidation and sulfation in man.

Full text

PDF
739

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARIAS I. M. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest. 1962 Dec;41:2233–2245. doi: 10.1172/JCI104682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aksoy I. A., Sochorová V., Weinshilboum R. M. Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation. Clin Pharmacol Ther. 1993 Nov;54(5):498–506. doi: 10.1038/clpt.1993.181. [DOI] [PubMed] [Google Scholar]
  3. Arias I. M., Gartner L. M., Cohen M., Ezzer J. B., Levi A. J. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med. 1969 Sep;47(3):395–409. doi: 10.1016/0002-9343(69)90224-1. [DOI] [PubMed] [Google Scholar]
  4. Baker C. A., Uno H., Johnson G. A. Minoxidil sulfation in the hair follicle. Skin Pharmacol. 1994;7(6):335–339. doi: 10.1159/000211315. [DOI] [PubMed] [Google Scholar]
  5. Bamforth K. J., Dalgliesh K., Coughtrie M. W. Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity? Eur J Pharmacol. 1992 May 1;228(1):15–21. doi: 10.1016/0926-6917(92)90006-x. [DOI] [PubMed] [Google Scholar]
  6. Bamforth K. J., Jones A. L., Roberts R. C., Coughtrie M. W. Common food additives are potent inhibitors of human liver 17 alpha-ethinyloestradiol and dopamine sulphotransferases. Biochem Pharmacol. 1993 Nov 17;46(10):1713–1720. doi: 10.1016/0006-2952(93)90575-h. [DOI] [PubMed] [Google Scholar]
  7. Barker E. V., Hume R., Hallas A., Coughtrie W. H. Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes. Endocrinology. 1994 Feb;134(2):982–989. doi: 10.1210/endo.134.2.8299591. [DOI] [PubMed] [Google Scholar]
  8. Barter R. A., Klaassen C. D. Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol Appl Pharmacol. 1994 Sep;128(1):9–17. doi: 10.1006/taap.1994.1174. [DOI] [PubMed] [Google Scholar]
  9. Bloxham R. A., Durbin G. M., Johnson T., Winterborn M. H. Chloramphenicol and phenobarbitone--a drug interaction. Arch Dis Child. 1979 Jan;54(1):76–77. doi: 10.1136/adc.54.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bock K. W., Schrenk D., Forster A., Griese E. U., Mörike K., Brockmeier D., Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994 Aug;4(4):209–218. doi: 10.1097/00008571-199408000-00005. [DOI] [PubMed] [Google Scholar]
  11. Bock K. W., Wiltfang J., Blume R., Ullrich D., Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol. 1987;31(6):677–683. doi: 10.1007/BF00541295. [DOI] [PubMed] [Google Scholar]
  12. Boelsterli U. A. Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab Rev. 1993;25(4):395–451. doi: 10.3109/03602539308993981. [DOI] [PubMed] [Google Scholar]
  13. Bonham Carter S. M., Rein G., Glover V., Sandler M., Caldwell J. Human platelet phenolsulphotransferase M and P: substrate specificities and correlation with in vivo sulphoconjugation of paracetamol and salicylamide. Br J Clin Pharmacol. 1983 Mar;15(3):323–330. doi: 10.1111/j.1365-2125.1983.tb01506.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bosma P. J., Chowdhury J. R., Bakker C., Gantla S., de Boer A., Oostra B. A., Lindhout D., Tytgat G. N., Jansen P. L., Oude Elferink R. P. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995 Nov 2;333(18):1171–1175. doi: 10.1056/NEJM199511023331802. [DOI] [PubMed] [Google Scholar]
  15. Brierley C. H., Burchell B. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays. 1993 Nov;15(11):749–754. doi: 10.1002/bies.950151108. [DOI] [PubMed] [Google Scholar]
  16. Burchell B., Brierley C. H., Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 1995;57(20):1819–1831. doi: 10.1016/0024-3205(95)02073-r. [DOI] [PubMed] [Google Scholar]
  17. Burchell B., Coughtrie M. W., Jackson M. R., Shepherd S. R., Harding D., Hume R. Genetic deficiency of bilirubin glucuronidation in rats and humans. Mol Aspects Med. 1987;9(5):429–455. doi: 10.1016/0098-2997(87)90007-0. [DOI] [PubMed] [Google Scholar]
  18. Burchell B., Coughtrie M. W., Jansen P. L. Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report of the Seventh International Workshop on Glucuronidation, September 1993, Pitlochry, Scotland. Hepatology. 1994 Dec;20(6):1622–1630. doi: 10.1002/hep.1840200636. [DOI] [PubMed] [Google Scholar]
  19. Chiba H., Komatsu K., Lee Y. C., Tomizuka T., Strott C. A. The 3'-terminal exon of the family of steroid and phenol sulfotransferase genes is spliced at the N-terminal glycine of the universally conserved GXXGXXK motif that forms the sulfonate donor binding site. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8176–8179. doi: 10.1073/pnas.92.18.8176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chou H. C., Lang N. P., Kadlubar F. F. Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res. 1995 Feb 1;55(3):525–529. [PubMed] [Google Scholar]
  21. Coughtrie M. W. Sulphation catalysed by the human cytosolic sulphotransferases--chemical defence or molecular terrorism? Hum Exp Toxicol. 1996 Jul;15(7):547–555. doi: 10.1177/096032719601500701. [DOI] [PubMed] [Google Scholar]
  22. Ding A., Ojingwa J. C., McDonagh A. F., Burlingame A. L., Benet L. Z. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3797–3801. doi: 10.1073/pnas.90.9.3797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dooley T. P., Mitchison H. M., Munroe P. B., Probst P., Neal M., Siciliano M. J., Deng Z., Doggett N. A., Callen D. F., Gardiner R. M. Mapping of two phenol sulphotransferase genes, STP and STM, to 16p: candidate genes for Batten disease. Biochem Biophys Res Commun. 1994 Nov 30;205(1):482–489. doi: 10.1006/bbrc.1994.2691. [DOI] [PubMed] [Google Scholar]
  24. Driscoll W. J., Komatsu K., Strott C. A. Proposed active site domain in estrogen sulfotransferase as determined by mutational analysis. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12328–12332. doi: 10.1073/pnas.92.26.12328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Duché J. C., Quérol-Ferrer V., Barré J., Mésangeau M., Tillement J. P. Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):392–398. [PubMed] [Google Scholar]
  26. Fevery J., Blanckaert N., Heirwegh K. P., Préaux A. M., Berthelot P. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest. 1977 Nov;60(5):970–979. doi: 10.1172/JCI108877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Fevery J. Pathogenesis of Gilbert's syndrome. Eur J Clin Invest. 1981 Dec;11(6):417–418. doi: 10.1111/j.1365-2362.1981.tb02006.x. [DOI] [PubMed] [Google Scholar]
  28. Gilissen R. A., Bamforth K. J., Stavenuiter J. F., Coughtrie M. W., Meerman J. H. Sulfation of aromatic hydroxamic acids and hydroxylamines by multiple forms of human liver sulfotransferases. Carcinogenesis. 1994 Jan;15(1):39–45. doi: 10.1093/carcin/15.1.39. [DOI] [PubMed] [Google Scholar]
  29. Glatt H., Pauly K., Czich A., Falany J. L., Falany C. N. Activation of benzylic alcohols to mutagens by rat and human sulfotransferases expressed in Escherichia coli. Eur J Pharmacol. 1995 Jul 1;293(2):173–181. doi: 10.1016/0926-6917(95)90002-0. [DOI] [PubMed] [Google Scholar]
  30. Glatt H., Pauly K., Frank H., Seidel A., Oesch F., Harvey R. G., Werle-Schneider G. Substance-dependent sex differences in the activation of benzylic alcohols to mutagens by hepatic sulfotransferases of the rat. Carcinogenesis. 1994 Nov;15(11):2605–2611. doi: 10.1093/carcin/15.11.2605. [DOI] [PubMed] [Google Scholar]
  31. Her C., Aksoy I. A., Kimura S., Brandriff B. F., Wasmuth J. J., Weinshilboum R. M. Human estrogen sulfotransferase gene (STE): cloning, structure, and chromosomal localization. Genomics. 1995 Sep 1;29(1):16–23. doi: 10.1006/geno.1995.1210. [DOI] [PubMed] [Google Scholar]
  32. Herman R. J., Loewen G. R., Antosh D. M., Taillon M. R., Hussein S., Verbeeck R. K. Analysis of polymorphic variation in drug metabolism: III. Glucuronidation and sulfation of diflunisal in man. Clin Invest Med. 1994 Aug;17(4):297–307. [PubMed] [Google Scholar]
  33. Ideo G., De Franchis R., Del Ninno E., Dioguardi N. Ethanol increases liver uridine-diphosphate-glucuronyltransferase. Experientia. 1971 Jan 15;27(1):24–25. doi: 10.1007/BF02137719. [DOI] [PubMed] [Google Scholar]
  34. Jones A. L., Roberts R. C., Colvin D. W., Rubin G. L., Coughtrie M. W. Reduced platelet phenolsulphotransferase activity towards dopamine and 5-hydroxytryptamine in migraine. Eur J Clin Pharmacol. 1995;49(1-2):109–114. doi: 10.1007/BF00192368. [DOI] [PubMed] [Google Scholar]
  35. Koiwai O., Nishizawa M., Hasada K., Aono S., Adachi Y., Mamiya N., Sato H. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet. 1995 Jul;4(7):1183–1186. doi: 10.1093/hmg/4.7.1183. [DOI] [PubMed] [Google Scholar]
  36. Macklon A. F., Savage R. L., Rawlins M. D. Gilbert's syndrome and drug metabolism. Clin Pharmacokinet. 1979 May-Jun;4(3):223–232. doi: 10.2165/00003088-197904030-00004. [DOI] [PubMed] [Google Scholar]
  37. Malaka-Zafriu K., Tsiouris I., Cassimos C. The effect of gentamicin on liver glucuronyl transferase. J Pediatr. 1973 Jan;82(1):118–120. doi: 10.1016/s0022-3476(73)80028-9. [DOI] [PubMed] [Google Scholar]
  38. Meisheri K. D., Cipkus L. A., Taylor C. J. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther. 1988 Jun;245(3):751–760. [PubMed] [Google Scholar]
  39. Meyers M., Slikker W., Vore M. Steroid D-ring glucuronides: characterization of a new class of cholestatic agents in the rat. J Pharmacol Exp Ther. 1981 Jul;218(1):63–73. [PubMed] [Google Scholar]
  40. Miller J. A. Sulfonation in chemical carcinogenesis--history and present status. Chem Biol Interact. 1994 Jun;92(1-3):329–341. doi: 10.1016/0009-2797(94)90074-4. [DOI] [PubMed] [Google Scholar]
  41. Miners J. O., Robson R. A., Birkett D. J. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol. 1984 Aug;18(2):240–243. doi: 10.1111/j.1365-2125.1984.tb02461.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Monaghan G., Clarke D. J., Povey S., See C. G., Boxer M., Burchell B. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics. 1994 Sep 15;23(2):496–499. doi: 10.1006/geno.1994.1531. [DOI] [PubMed] [Google Scholar]
  43. Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 1996 Mar 2;347(9001):578–581. doi: 10.1016/s0140-6736(96)91273-8. [DOI] [PubMed] [Google Scholar]
  44. Nagata K., Ozawa S., Miyata M., Shimada M., Gong D. W., Yamazoe Y., Kato R. Isolation and expression of a cDNA encoding a male-specific rat sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene. J Biol Chem. 1993 Nov 25;268(33):24720–24725. [PubMed] [Google Scholar]
  45. Osborne N. J., Tonkin A. L., Miners J. O. Interethnic differences in drug glucuronidation: a comparison of paracetamol metabolism in Caucasians and Chinese. Br J Clin Pharmacol. 1991 Dec;32(6):765–767. [PMC free article] [PubMed] [Google Scholar]
  46. Otterness D. M., Mohrenweiser H. W., Brandriff B. F., Weinshilboum R. M. Dehydroepiandrosterone sulfotransferase gene (STD): localization to human chromosome band 19q13.3. Cytogenet Cell Genet. 1995;70(1-2):45–47. doi: 10.1159/000133988. [DOI] [PubMed] [Google Scholar]
  47. Ouzzine M., Pillot T., Fournel-Gigleux S., Magdalou J., Burchell B., Siest G. Expression and role of the human liver UDP-glucuronosyltransferase UGT1*6 analyzed by specific antibodies raised against a hybrid protein produced in Escherichia coli. Arch Biochem Biophys. 1994 Apr;310(1):196–204. doi: 10.1006/abbi.1994.1157. [DOI] [PubMed] [Google Scholar]
  48. Owens I. S., Ritter J. K. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes. Pharmacogenetics. 1992 Jun;2(3):93–108. doi: 10.1097/00008571-199206000-00001. [DOI] [PubMed] [Google Scholar]
  49. Ozawa S., Chou H. C., Kadlubar F. F., Nagata K., Yamazoe Y., Kato R. Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine by cDNA-expressed human and rat arylsulfotransferases. Jpn J Cancer Res. 1994 Dec;85(12):1220–1228. doi: 10.1111/j.1349-7006.1994.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Panesar S. K., Orr J. M., Farrell K., Burton R. W., Kassahun K., Abbott F. S. The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol. 1989 Mar;27(3):323–328. doi: 10.1111/j.1365-2125.1989.tb05372.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pang S., MacGillivray M., Wang M., Jeffries S., Clark A., Rosenthal I., Wiegensberg M., Riddick L. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion. J Clin Endocrinol Metab. 1991 Jul;73(1):166–174. doi: 10.1210/jcem-73-1-166. [DOI] [PubMed] [Google Scholar]
  52. Pantuck E. J., Pantuck C. B., Anderson K. E., Wattenberg L. W., Conney A. H., Kappas A. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther. 1984 Feb;35(2):161–169. doi: 10.1038/clpt.1984.22. [DOI] [PubMed] [Google Scholar]
  53. Patel M., Tang B. K., Grant D. M., Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics. 1995 Oct;5(5):287–297. doi: 10.1097/00008571-199510000-00004. [DOI] [PubMed] [Google Scholar]
  54. Paul D., Standifer K. M., Inturrisi C. E., Pasternak G. W. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989 Nov;251(2):477–483. [PubMed] [Google Scholar]
  55. Pillot T., Ouzzine M., Fournel-Gigleux S., Lafaurie C., Radominska A., Burchell B., Siest G., Magdalou J. Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4. J Biol Chem. 1993 Dec 5;268(34):25636–25642. [PubMed] [Google Scholar]
  56. Remmel R. P., Burchell B. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol. 1993 Aug 17;46(4):559–566. doi: 10.1016/0006-2952(93)90538-8. [DOI] [PubMed] [Google Scholar]
  57. Runge-Morris M., Wilusz J. Suppression of hydroxysteroid sulfotransferase-a gene expression by 3-methylcholanthrene. Toxicol Appl Pharmacol. 1994 Mar;125(1):133–141. doi: 10.1006/taap.1994.1057. [DOI] [PubMed] [Google Scholar]
  58. SZABO L., EBREY P. STUDIES ON THE INHERITANCE OF CRIGLER--NAJJAR'S SYNDROME BY THE MENTHOL TEST. Acta Paediatr Acad Sci Hung. 1963;4:153–158. [PubMed] [Google Scholar]
  59. Saito K., Kaneko H., Sato K., Yoshitake A., Yamada H. Hepatic UDP-glucuronyltransferase(s) activity toward thyroid hormones in rats: induction and effects on serum thyroid hormone levels following treatment with various enzyme inducers. Toxicol Appl Pharmacol. 1991 Oct;111(1):99–106. doi: 10.1016/0041-008x(91)90138-5. [DOI] [PubMed] [Google Scholar]
  60. Salman K., Spielvogel R. L., Shulman L. H., Miller J. L., Vanderlinde R. E., Rose L. I. Serum androstanediol glucuronide in women with facial hirsutism. J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):411–414. doi: 10.1016/0190-9622(92)70064-m. [DOI] [PubMed] [Google Scholar]
  61. Schuetz E. G., Hazelton G. A., Hall J., Watkins P. B., Klaassen C. D., Guzelian P. S. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem. 1986 Jun 25;261(18):8270–8275. [PubMed] [Google Scholar]
  62. Senafi S. B., Clarke D. J., Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J. 1994 Oct 1;303(Pt 1):233–240. doi: 10.1042/bj3030233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Sharp S., Coughtrie M. W., Forbes K. J., Hume R. Preparation and characterization of anti-peptide antibodies directed against human phenol and hydroxysteroid sulphotransferases. J Pharmacol Toxicol Methods. 1995 Oct;34(2):89–95. doi: 10.1016/1056-8719(95)00041-f. [DOI] [PubMed] [Google Scholar]
  64. Sharp S., Mak L. Y., Smith D. J., Coughtrie M. W. Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs--implications for adverse drug reactions. Xenobiotica. 1992 Jan;22(1):13–25. doi: 10.3109/00498259209053098. [DOI] [PubMed] [Google Scholar]
  65. Slikker W., Jr, Vore M., Bailey J. R., Meyers M., Montgomery C. Hepatotoxic effects of estradiol-17 beta-D-glucuronide in the rat and monkey. J Pharmacol Exp Ther. 1983 Apr;225(1):138–143. [PubMed] [Google Scholar]
  66. Spahn-Langguth H., Benet L. Z. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev. 1992;24(1):5–47. doi: 10.3109/03602539208996289. [DOI] [PubMed] [Google Scholar]
  67. Stoehr G. P., Kroboth P. D., Juhl R. P., Wender D. B., Phillips J. P., Smith R. B. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984 Nov;36(5):683–690. doi: 10.1038/clpt.1984.240. [DOI] [PubMed] [Google Scholar]
  68. Sutherland L., Ebner T., Burchell B. The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol. 1993 Jan 26;45(2):295–301. doi: 10.1016/0006-2952(93)90064-4. [DOI] [PubMed] [Google Scholar]
  69. Tephly T. R., Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci. 1990 Jul;11(7):276–279. doi: 10.1016/0165-6147(90)90008-v. [DOI] [PubMed] [Google Scholar]
  70. Thompson D. L., Horton N., Rittmaster R. S. Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women. Clin Endocrinol (Oxf) 1990 Mar;32(3):283–292. doi: 10.1111/j.1365-2265.1990.tb00868.x. [DOI] [PubMed] [Google Scholar]
  71. Ullrich D., Sieg A., Blume R., Bock K. W., Schröter W., Bircher J. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest. 1987 Jun;17(3):237–240. doi: 10.1111/j.1365-2362.1987.tb01242.x. [DOI] [PubMed] [Google Scholar]
  72. Vincent-Viry M., Cossy C., Galteau M. M., Gueguen R., Magdalou J., Nicolas A., Leroy P., Siest G. Lack of a genetic polymorphism in the glucuronidation of fenofibric acid. Pharmacogenetics. 1995 Feb;5(1):50–52. doi: 10.1097/00008571-199502000-00006. [DOI] [PubMed] [Google Scholar]
  73. Visser T. J., Kaptein E., Gijzel A. L., de Herder W. W., Ebner T., Burchell B. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Lett. 1993 Jun 21;324(3):358–360. doi: 10.1016/0014-5793(93)80151-j. [DOI] [PubMed] [Google Scholar]
  74. Vree T. B., Van Den Biggelaar-Martea M., Verwey-Van Wissen C. P., Vree M. L., Guelen P. J. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol. 1993 May;35(5):467–472. doi: 10.1111/j.1365-2125.1993.tb04171.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Walle T., Eaton E. A., Walle U. K. Quercetin, a potent and specific inhibitor of the human P-form phenosulfotransferase. Biochem Pharmacol. 1995 Aug 25;50(5):731–734. doi: 10.1016/0006-2952(95)00190-b. [DOI] [PubMed] [Google Scholar]
  76. Weinshilboum R. Sulfotransferase pharmacogenetics. Pharmacol Ther. 1990;45(1):93–107. doi: 10.1016/0163-7258(90)90010-y. [DOI] [PubMed] [Google Scholar]
  77. Witzmann F., Coughtrie M., Fultz C., Lipscomb J. Effect of structurally diverse peroxisome proliferators on rat hepatic sulfotransferase. Chem Biol Interact. 1996 Jan 5;99(1-3):73–84. doi: 10.1016/0009-2797(95)03661-x. [DOI] [PubMed] [Google Scholar]
  78. Wooster R., Sutherland L., Ebner T., Clarke D., Da Cruz e Silva O., Burchell B. Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family. Biochem J. 1991 Sep 1;278(Pt 2):465–469. doi: 10.1042/bj2780465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Yamazoe Y., Nagata K., Ozawa S., Kato R. Structural similarity and diversity of sulfotransferases. Chem Biol Interact. 1994 Jun;92(1-3):107–117. doi: 10.1016/0009-2797(94)90057-4. [DOI] [PubMed] [Google Scholar]
  80. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol. 1989 Dec;28(6):629–637. doi: 10.1111/j.1365-2125.1989.tb03555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. de Morais S. M., Wells P. G. Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology. 1989 Aug;10(2):163–167. doi: 10.1002/hep.1840100207. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES